It increases insulin secretion, enhances glucose absorption by skeletal muscle cells, and decreases inflammation, all of which contribute to improved metabolic health
Over 26 weeks, including a dose-escalation period of up to 6 weeks, researchers observed mean percentage weight reductions of 6.0% to 10.8% across the cagrilintide dose groups compared to just 3.0% with placebo
KLOW provides researchers with an opportunity to investigate how multiple peptide signaling pathways interact to regulate cellular communication, inflammatory physiology, tissue adaptation, and the biological mechanisms responsible for maintaining structural integrity under changing physiological conditions
Gastroenterologists generally prefer Miralax for GLP-1 users
On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
